Biocon is well renowned company of the pharmaceuticals sector and hold significant position in its field.For long term investment this counter is always counted to be part of the portfolio.The resulted posted by the company is not satisfactory and forcing to have second thought regarding investment in this stock.
About The Financials
Results for Sep 2008 shows EBITDA margin in pharma segment plummeting to 25.95% from 37.11% of Q1 FY 09. The dent on profitability has been due to rise in raw material costs from 43% of net sales in Q1 of FY 09 to 53.50% in Q2 of FY 09.Total income of Biocon during second quarter ending Sept. 08 was at Rs.442 crores against Rs. 279 crores of the corresponding quarter in the previous year. However, Q2 FY 08 includes the workings of its enzymes business, which was transferred to third party, effective from 01-10-07. Hence, it is appropriate to compare the results of the company on sequential basis.
Net sales rose to Rs.439.30 crores in Q2 from Rs.263.93 crores in Q1 of FY 09. Inspite of this, profit after tax but before exceptional items, has been flat at Rs.49.84 crores against Rs.48.55 crores of Q1. After forex losses provisions of Rs.25.45 crores during Q2, PAT was placed at Rs.25.02 crores against Rs.15.04 crores of Q1.
The company has issued 1 : 1 bonus on 15-09-08, due to which paid up equity of the company increased to Rs.100 crores. This has resulted into an EPS of Re.1.25 for the quarter while it is at Rs.2 for first half of FY 09.
About The Stock
The stock is near top its 52 week low but the pressure on margins may drown it further. The stock is expected to correct more because of the disappointing results.Fresh investors need patient to invest in this stock.
Disclaimer : I do not have any personal holding in this stock.